Akorn Inc (AKRX.OQ)
Latest Key Developments (Source: Significant Developments)
April 24 (Reuters) - Akorn Inc
Akorn Inc: Q4 gaap earnings per share $0.26 . expects 2017 adjusted net income per diluted share (non-gaap) $1.53 - $1.72 . Akorn provides fourth quarter and full year 2016 results and outlines full year 2017 guidance . Q4 revenue $284 million versus i/b/e/s view $288 million . Q4 earnings per share view $0.57 -- Thomson Reuters I/B/E/S . Q4 adjusted non-gaap earnings per share $0.58 including items . sees 2017 consolidated revenue, $ 1,010 million- $ 1,060 million . Akorn's guidance includes $30 to $60 million from new product launches of products already approved and those expected to be approved in 2017 . sees 2017 gaap net income per diluted share $0.99 -$1.18 . sees 2017 adjusted net income per diluted share (non-gaap) $1.53- $1.72 .Fy2017 earnings per share view $2.17, revenue view $1.12 billion -- Thomson Reuters I/B/E/S. Full Article
Akorn, Inc:Says Duane A. Portwood, will join Akorn as Executive Vice President and Chief Financial Officer, effective October 30, 2015.Interim Chief Financial Officer Randall Pollard will continue to serve as Senior Vice President, Chief Accounting Officer and Corporate Controller after Portwood's appointment. Full Article
Akorn Inc:Says It has launched Doxercalciferol Injection Solution, 4 mcg/2 mL in 2mL single-use vials. The launch follows an approval of an abbreviated new drug application for the product from the U.S. Food and Drug Administration on May 7, 2015. Full Article
FRANKFURT, May 12 The head of German healthcare group Fresenius SE said he would abstain from the takeover market for now, after striking three deals worth billions of euros in total since taking over less than a year ago.